142 related articles for article (PubMed ID: 12517432)
1. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
Hirayama F; Koshio H; Katayama N; Ishihara T; Kaizawa H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kurihara H; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2003 Feb; 11(3):367-81. PubMed ID: 12517432
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
[TBL] [Abstract][Full Text] [Related]
3. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
[TBL] [Abstract][Full Text] [Related]
5. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
Buckman BO; Mohan R; Koovakkat S; Liang A; Trinh L; Morrissey MM
Bioorg Med Chem Lett; 1998 Aug; 8(16):2235-40. PubMed ID: 9873520
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
[TBL] [Abstract][Full Text] [Related]
9. 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors.
Rewinkel JB; Lucas H; van Galen PJ; Noach AB; van Dinther TG; Rood AM; Jenneboer AJ; van Boeckel CA
Bioorg Med Chem Lett; 1999 Mar; 9(5):685-90. PubMed ID: 10201829
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.
de Candia M; Fiorella F; Lopopolo G; Carotti A; Romano MR; Lograno MD; Martel S; Carrupt PA; Belviso BD; Caliandro R; Altomare C
J Med Chem; 2013 Nov; 56(21):8696-711. PubMed ID: 24102612
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
[TBL] [Abstract][Full Text] [Related]
13. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities.
Nishida H; Miyazaki Y; Mukaihira T; Saitoh F; Fukui M; Harada K; Itoh M; Muraoka A; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1187-94. PubMed ID: 12237534
[TBL] [Abstract][Full Text] [Related]
15. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor.
Nishida H; Miyazaki Y; Kitamura Y; Ohashi M; Matsusue T; Okamoto A; Hosaka Y; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1237-44. PubMed ID: 11605647
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Nagamochi M; Kobayashi S; Komoriya S; Yokomizo A; Muto R; Yamaguchi M; Osanai K; Suzuki M; Kanno H
Bioorg Med Chem; 2009 Feb; 17(3):1193-206. PubMed ID: 19128974
[TBL] [Abstract][Full Text] [Related]
18. Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.
Ishihara T; Koga Y; Mori K; Sugasawa K; Iwatsuki Y; Hirayama F
Bioorg Med Chem; 2014 Nov; 22(22):6324-32. PubMed ID: 25438755
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.
Chou YL; Davey DD; Eagen KA; Griedel BD; Karanjawala R; Phillips GB; Sacchi KL; Shaw KJ; Wu SC; Lentz D; Liang AM; Trinh L; Morrissey MM; Kochanny MJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):507-11. PubMed ID: 12565961
[TBL] [Abstract][Full Text] [Related]
20. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
